Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting

References

• Navari RM, Aapro M. Antiemetic prophylaxis for Chemotherapy-Induced Nausea and vomiting. N Engl J Med. 2016;374(14):1356–1367.
   PubMed Web of Science ®Google Scholar
• NCCN National Comprehensive Cancer Network. Antiemesis: Clinical Practice Guidelines in Oncology, v 2. 2016. Antiemesis; [cited 2020 Nov]. Available from: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.
   Google Scholar
• Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119–v133.
   PubMed Web of Science ®Google Scholar
• NCCN National Comprehensive Cancer Network. Antiemesis: Clinical Practice Guidelines in Oncology, v 2.2020 Antiemesis; [cited 2020 Nov]. Available from: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.
   Google Scholar
• Zhang Z, Zhang Y, Chen G, et al. Olanzapine-based triple regimens versus neurokinin-1 receptor antagonist-based triple regimens in preventing chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy: a network meta-analysis. Oncologist. 2018;23(5):603–616.
   PubMed Web of Science ®Google Scholar
• Alhifany AA, McBride A, Almutairi AR, et al. Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network Meta-analysis. Support Care Cancer. 2020;28(3):1031–1039.
   PubMed Web of Science ®Google Scholar
• Abe M, Kasamatsu Y, Kado N, et al. Efficacy of olanzapine combined therapy for patients receiving highly emetogenic chemotherapy resistant to standard antiemetic therapy. Biomed Res Int. 2015;2015:1–6.
   Web of Science ®Google Scholar
• Zhang L, Qu X, Teng Y, et al. Efficacy of thalidomide in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy: a randomized, multicenter, Double-Blind, Placebo-Controlled phase III trial (CLOG1302 study). J Clin Oncol. 2017;35(31):3558–3565.
   PubMed Web of Science ®Google Scholar
• Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25(7):1328–1333.
   PubMed Web of Science ®Google Scholar
• Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer. 2008;112(9):2080–2087.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25(7):1340–1346.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Kwatra G, Alice KP, et al. Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study. Support Care Cancer. 2017;25(1):145–154.
   PubMed Web of Science ®Google Scholar
• Shumway NM, Terrazzino SE, Jones CB. A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy-induced nausea and vomiting. J Clin Oncol. 2009;27(15_suppl):9633–9633.
   Google Scholar
• Babu G, Saldanha SC, Kuntegowdanahalli Chinnagiriyappa L, et al. The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India. Chemother Res Pract. 2016;2016:3439707.
   PubMedGoogle Scholar
• Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9(5):188–195.
   PubMedGoogle Scholar
• Navari RM, Nagy CK, Le-Rademacher J, et al. Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J Community Support Oncol. 2016;14(4):141–147.
   Google Scholar
• RedBook Online [subscription database online]. Greenwood Village, CO: Truven Health Analytics, Inc. updated periodically; [cited 2020 Nov]. Available from: http://micromedex.com/products/product-suites/clinical-knowledge/redbook.
   Google Scholar
• Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(2):242–249.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Yamanaka T, Hashimoto H, et al. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol. 2016;27(8):1601–1606.
   PubMed Web of Science ®Google Scholar
• Tsuji D, Suzuki K, Kawasaki Y, et al. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial. Support Care Cancer. 2019;27(3):1139–1147.
   PubMed Web of Science ®Google Scholar
• Bonetti A, Giuliani J. Implications of drugs with rebate in Europe. Lancet Reg Health Eur. 2021;3:100060.
   PubMedGoogle Scholar
• Giuliani J, Bonetti A. Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment. Expert Rev Pharmacoecon Outcomes Res. 2019;19(5):505–508.
   PubMed Web of Science ®Google Scholar
• Giuliani J, Bonetti A. Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data. Curr Opin Oncol. 2020;32(4):269–273.
   PubMed Web of Science ®Google Scholar
• Choi BM, Abraham RB, Halawah H, et al. Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities. J Med Econ. 2021;24(sup1):34–41.
   PubMed Web of Science ®Google Scholar
• Alkhatib NS, Abraham I. The six Delta platform for outcome-based contracting for pharmaceuticals. J Med Econ. 2020;23(11):1209–1214.
   PubMed Web of Science ®Google Scholar